Skip to main content
CRL
NYSE Industrial Applications And Services

Charles River Posts Q2 Revenue of $1.0B, Net Loss Driven by $63.7M Divestiture Charge

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$257
Mkt Cap
$11.277B
52W Low
$144.26
52W High
$242.73
52W Position info
78% above low
Off High info
at 52W high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

CRL sits 78% above its 52-week low of $144.26.

Summary

Charles River reported Q2 revenue of $1.0 billion and a net loss of $1.5 million, driven by a $63.7 million divestiture loss. The company is restructuring, acquiring a key NHP supplier, and the CEO adopted a 10b5-1 trading plan.


Key Events · Earnings and Guidance · CRL

  • Q2 Revenue $1.0B, Net Loss $1.5M

    Revenue of $1.004 billion was down 2.7% year-over-year, while a net loss of $1.5 million was driven by a $63.7 million loss on the CDMO and Cell Solutions divestiture.

  • Divestiture Losses Reshape Portfolio

    The CDMO and Cell Solutions sale to GI Partners resulted in a $63.7 million pre-tax loss this quarter ($181.7 million YTD). The European Discovery sale to IQVIA yielded a $0.3 million gain.

  • Cambodian NHP Supplier Acquired for $507M

    The acquisition of a Cambodian non-human primate supplier closed in January 2026 for $507.3 million, securing a critical supply chain for the DSA segment.

  • Restructuring Charges Continue

    Restructuring costs were $23.1 million in Q2 and $54.6 million YTD, part of a plan to achieve $300 million in annualized savings by end of 2026.


Analysis · CRL · Industrial Applications And Services

Charles River's Q2 results present a mixed picture: revenue held at $1.0 billion, but a net loss of $1.5 million was driven by a $63.7 million loss on the CDMO and Cell Solutions divestiture. Operating income improved to $119.9 million from $100.1 million a year ago, helped by lower amortization and a gain on a sale-leaseback. The company is actively reshaping its portfolio—selling underperforming businesses while acquiring a Cambodian NHP supplier for $507 million to secure a critical supply chain. Restructuring charges of $23.1 million this quarter reflect ongoing cost-cutting. The CEO adopted a 10b5-1 plan to sell up to 14,000 shares starting September 1, which may weigh on sentiment despite the operational improvements.

At the time of this filing, CRL was trading at $257.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $144.26 to $242.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRL - Latest Insights

CRL
Aug 05, 2026, 8:28 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $253.00
Real-time Price: $264.00 info
Change: +$11.00 (+4%) info
Market Cap: $11.277B info
CRL
Aug 05, 2026, 7:33 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $253.00
Real-time Price: $264.00 info
Change: +$11.00 (+4%) info
Market Cap: $11.277B info
CRL
Aug 05, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $253.00
Real-time Price: $264.00 info
Change: +$11.00 (+4%) info
Market Cap: $11.277B info
CRL
May 11, 2026, 5:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $168.46
Real-time Price: $264.00 info
Change: +$95.54 (+57%) info
Market Cap: $11.277B info
CRL
May 07, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $181.68
Real-time Price: $264.00 info
Change: +$82.32 (+45%) info
Market Cap: $11.277B info